A5055301443- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Breast Lesions and Carcinomas
- Economic and Financial Impacts of Cancer
- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Cancer survivorship and care
- Cancer Cells and Metastasis
- Breast Implant and Reconstruction
- Cancer Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- Nutrition, Genetics, and Disease
- Genetic factors in colorectal cancer
- Neutropenia and Cancer Infections
Dana-Farber Cancer Institute
2016-2025
Harvard University
2015-2024
Boston University
1993-2024
Brigham and Women's Hospital
2012-2024
Dana-Farber Brigham Cancer Center
2015-2024
Women's Hospital
2024
Target (United States)
2023
International Breast Cancer Study Group
2015-2022
Alliance for Clinical Trials in Oncology
2014-2022
CancerCare
2019-2021
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer.An American Society Clinical Oncology (ASCO) Expert Panel conducted systematic review literature available through February 2004 on SNB early-stage cancer. The panel developed clinicians and patients regarding appropriate lymph identification sampling procedure from hereon referred to as SNB. was reviewed by selected experts field ASCO Health Services Committee approved Board Directors.The...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group neoplastic lesions ducts. The goal for management DCIS is to prevent development invasive cancer. This manuscript focuses on NCCN Guidelines Panel recommendations workup, primary treatment, risk reduction strategies, and surveillance specific DCIS.
Several new systemic therapy options have become available for patients with metastatic breast cancer, which led to improvements in survival. In addition patient and clinical factors, the treatment selection primarily depends on tumor biology (hormone-receptor status HER2-status). The NCCN Guidelines specific workup of recurrent/stage IV cancer are discussed this article.
Abstract BACKGROUND Women with HER‐2 overexpressing metastatic breast carcinoma benefit from trastuzumab‐based therapy, but trastuzumab does not cross the blood‐brain barrier. The authors characterized central nervous system (CNS) disease in these women. METHODS Using pharmacy records, retrospectively identified 153 women treated alone or chemotherapy for HER‐2–positive at Dana‐Farber Partners Cancer Care June 1998 to December 2000. A study cohort of 122 patients was after excluding without...
Purpose Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than single agent alone. EGF104900 compared the activity of alone or combination with trastuzumab patients ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC). Patients Methods MBC who experienced progression on prior trastuzumab-containing regimens were randomly assigned to receive either...
To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians update the 2005 clinical practice guideline on use of sentinel node biopsy (SNB) for patients with early-stage breast cancer.The American Society Clinical Oncology convened an Update Committee experts in medical oncology, pathology, surgical implementation, advocacy. A systematic review literature was conducted from February 2004 January 2013 Medline. Guideline were based evidence...
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines Breast Cancer include recommendations clinical management of carcinoma in situ, cancer, Paget disease, phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall ductal situ workup locoregional early stage cancer. For full version Cancer, visit NCCN.org .
To update the ASCO clinical practice guideline on adjuvant endocrine therapy basis of emerging data optimal duration treatment, particularly tamoxifen.ASCO convened Update Committee and conducted a systematic review randomized trials from January 2009 to June 2013 analyzed three historical trials. Guideline recommendations were based Committee's evidence. Outcomes interest included survival, disease recurrence, adverse events.This reflects tamoxifen treatment. There have been five studies...
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
Suppression of ovarian estrogen production reduces the recurrence hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.We randomly assigned 3066 stratified according prior receipt or nonreceipt chemotherapy, receive 5 years tamoxifen, plus suppression, exemestane suppression. The primary analysis tested hypothesis that suppression would improve disease-free survival, as compared with alone. In analysis, 46.7% patients had...
No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these have been ineligible the pivotal trials adjuvant trastuzumab.We performed an uncontrolled, single-group, multicenter, investigator-initiated study paclitaxel and trastuzumab in 406 tumors measuring up to 3 cm greatest dimension. Patients received weekly 12 weeks, followed by 9 months monotherapy. The primary end point...
We analyzed the use of alternative medicine by women who had received standard therapy for early-stage breast cancer diagnosed between September 1993 and 1995.
Phase II trials suggested that weekly paclitaxel might be more effective and less toxic than every-3-weeks administration for metastatic breast cancer (MBC). Cancer Leukemia Group B (CALGB) protocol 9840 was initiated to address this question. Subsequently trastuzumab demonstrated improve outcomes of therapy human epidermal growth factor receptor-2 (HER-2)-positive patients, therefore incorporated. Because inhibition HER-family signaling had potential efficacy even without HER-2...
A MESSAGE FROM ASCO’S PRESIDENT I am pleased to present Clinical Cancer Advances 2017, which highlights the most promising advances in patient-oriented cancer research over past year. The report gives us an opportunity reflect on what exciting time it is for and how swiftly our understanding of has improved. One year ago, White House announced national Moonshot program accelerate progress against cancer. This shared vision reinvigorated community, identified new areas scientific...
The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer.
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC).The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review evidence from 2008 through 2015 create informed by that evidence. Outcomes interest included sequencing hormonal agents, agents compared chemotherapy, targeted biologic therapy, and treatment premenopausal women. This guideline puts forth as HR-positive MBC.Sequential...
Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall (OS) analysis from is reported here.Patients HER2-positive MBC whose disease progressed during prior trastuzumab-based therapies were...